british association of dermatologists biologic interventions register (badbir) adverse events
TRANSCRIPT
![Page 1: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/1.jpg)
British Association of Dermatologists Biologic Interventions Register (BADBIR)
Adverse Events
![Page 2: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/2.jpg)
1. BADBIR – Rationale, aims and design
2. Concentrating on one aim – safety data collected as adverse events
1. Why and how does BADBIR collect adverse event (AE) data?
2. What is an adverse event?
3. What do we do with the data?
Overview of presentation
![Page 3: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/3.jpg)
BADBIR – Rationale, aims and design
![Page 4: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/4.jpg)
Historically: How is Potential Harm of Biologic Therapy assessed?
Phase I/II– Phase III
• Spontaneous pharmacovigilance
• Observational cohortsNational registers
Short-term safety of biologics has been evaluated in clinical trials
Some long-term safety data on anti-TNF drugs available from use in other conditions e.g. inflammatory arthritis, Crohn’s disease
![Page 5: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/5.jpg)
Rationale for BADBIR
• Potential for serious side effects after long-term use– efalizumab (had marketing license withdrawn)
Patients with severe psoriasis are likely to• be obese • smoke• abuse alcohol • have a high risk of cardio-vascular disease • be exposed to different types of drugs, e.g.
phototherapy– Therefore, data on the safety of biologic use in other
conditions cannot be directly extrapolated to psoriasis
Recommendation from BAD
All patients treated with biologic agents be registered with BADBIR
![Page 6: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/6.jpg)
Aim of BADBIR
To investigate the long-term outcome of psoriasis patients treated with biologic agents, with particular reference to safety
Primary endpoints of interestmalignancy infection requiring hospitalisation serious adverse eventsdeath
![Page 7: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/7.jpg)
BADBIR Study DesignObservational Cohort Study
Inclusion Criteria (both cohorts)
Diagnosis of psoriasis
Aged 16 years or over
Willing to provide written informed consent
Under the care of a dermatologist
![Page 8: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/8.jpg)
BADBIR Study DesignObservational Cohort Study
Inclusion Criteria (both cohorts)
Diagnosis of psoriasis
Aged 16 years or over
Willing to provide written informed consent
Under the care of a dermatologist
Biologic CohortStarting / switching
BIOLOGIC therapy in last 6 months
adalimumab
etanercept
infliximab
ustekinumab
![Page 9: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/9.jpg)
BADBIR Study DesignObservational Cohort Study
Inclusion Criteria (both cohorts)
Diagnosis of psoriasis
Aged 16 years or over
Willing to provide written informed consent
Under the care of a dermatologist
Biologic Cohort Conventional cohort(anti-psoriatic therapy)
vs.
Starting / switching BIOLOGIC therapy in
last 6 months
adalimumab etanercept
infliximab
ustekinumab
Starting* / switching CONVENTIONAL therapy
in last 6 months
acitretin ciclosporin fumaric acid esters hydroxycarbamide methotrexate PUVA
Conventional cohort additional criteria:
•Must be biologic naive
•* If starting therapy, PASI ≥10 and a DLQI >10
![Page 10: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/10.jpg)
– What is an adverse event (AE)?
– What is a serious adverse event (SAE)?
– How do we collect adverse event data?
– What do BADBIR do with the data?
Concentrating on one aim – safetydata collected as adverse events
![Page 11: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/11.jpg)
What is an Adverse Event (AE)?
• Any untoward medical occurrence which affects the patient’s health whilst he/she is on the Register
• Does not necessarily have causal relationship with treatment
• Applies equally to Conventional Cohort and Biologic Cohort even if they have stopped treatment
![Page 12: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/12.jpg)
What is an Adverse Event?
• Includes all symptoms, illnesses, accidents, unfavourable and unintended signs (including lab findings that are clinically relevant)
• Pregnancies
• Deaths
![Page 13: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/13.jpg)
AEs in those with pre-existing disease
• Exacerbations – e.g. COPD, worsening multiple sclerosis,
psoriasis flare-up
• Increase in frequency of episodes – e.g. epilepsy or asthma attacks
![Page 14: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/14.jpg)
What are Serious Adverse Events (SAEs)?
• Result in death• Hospitalisation• IV antibiotics/antivirals/antifungals• Significant loss of function or disability• Congenital malformation• Life threatening in any way
![Page 15: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/15.jpg)
Hospitalisation
• Admission to hospital at least overnight
• Not: – day care,
– outpatient procedures or
– A & E visits
![Page 16: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/16.jpg)
Significant loss of function/disability
• An event which causes a disruption of one’s ability to carry out normal life functions or daily activities
• This does not have to be permanent or irreversible
![Page 17: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/17.jpg)
Life Threatening
• Includes events which are short-lived e.g. anaphylactic shock
• Need not result in hospitalisation
• Patient at immediate risk of death from the event as it occurred
![Page 18: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/18.jpg)
What is NOT an adverse event
• One which occurred before patient was registered with BADBIR
• Elective surgery which was planned before patient was registered with BADBIR (although we still would like to know about these)– But it is an adverse event or SAEs if
complications develop
![Page 19: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/19.jpg)
• Collect data on all adverse events
• Compare event type and rates between Conventional Group and Biologic Group
How are they collected?
![Page 20: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/20.jpg)
Where does AE data come from?
1. Dermatology team at each follow up
2. NHS Information Centre
Patients are flagged for the occurrence of malignancy and/or death
![Page 21: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/21.jpg)
Clinician Reporting of SAEs
• Every 6 months, clinicians are asked to submit data to BADBIR with reference to changes in therapy and adverse events within the period
• This is how BADBIR identifies the majority of SAEs
![Page 22: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/22.jpg)
Entering an adverse event on the database
• To add screenshot
![Page 23: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/23.jpg)
Events of Special Interest Reports
• Currently include:– aplastic anaemia,
pancytopaenia, neutropaenia
– serious infections
– lymphoproliferative disease
– pulmonary embolism
– heart failure
– myocardial infarction
– demyelination, optic neuritis
– pregnancy
– malignancy
– skin cancer
– death
– hepatic events
![Page 24: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/24.jpg)
Event of Special Interest
![Page 25: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/25.jpg)
Adverse event page
![Page 26: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/26.jpg)
NHS Information Centre (NHSIC) Report
• Patients identifiable information (name, dob) are flagged with the NHS IC
• A report on all flagged patients is provided by NHS IC to BADBIR (approx 4 times per year) with the following information – Malignancies (including those prior to biologic)
– Deaths
![Page 27: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/27.jpg)
What does the BADBIR Do With Adverse Events Data?
![Page 28: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/28.jpg)
What does the BADBIR Do With Adverse Events Data?
• Reporting of SAEs to drug companies
• Recording of adverse outcomes on
database
• Scientific analysis
![Page 29: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/29.jpg)
Reporting of SAEs to Drug Companies
• 24-hour reports• Company 6 monthly reports
BADBIR have an obligation to report all SAEs to the companies for drug regulatory authority purposes
Provided in the following way:
![Page 30: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/30.jpg)
Events of Special Interest (ESI)
BADBIR is required to provide more detailed information on events of special interest to the companies:
• These include• Any Serious Infection
• TB
• Lymphoproliferative Tumour
• Heart Failure
• Central Demyelinating Disease
• Pancytopaenia/Aplastic Anaemia
![Page 31: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/31.jpg)
6-Monthly Reports
• Produced for each drug company involved
• Categorises individual SAE reported during period of patient exposure to their product
![Page 32: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/32.jpg)
Recording of Adverse Events on database
Coding for ease of retrieval for analysis and presentation
![Page 33: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/33.jpg)
MedDRA
• Medical Dictionary for Regulatory Activities
• Computer programme which allows individual adverse outcomes to be coded and stored on database in specific groups
• These groups can be pulled out, cross referenced, counted and compared
![Page 34: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/34.jpg)
Structural Hierarchy of the MedDRA Terminology
System Order Class
High Level Group Term
High Level Term
Preferred Term
Lowest Level Term (LLT)
(PT)
(HLT)
(HLGT)
(SOC)
![Page 35: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/35.jpg)
Structural Hierarchy of the MedDRA Terminology
System Order Class
High Level Group Term
High Level Term
Preferred Term
Lowest Level Term
Myocardial Infarction
Heart attack
![Page 36: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/36.jpg)
Structural Hierarchy of the MedDRA Terminology
System Order Class
High Level Group Term
High Level Term
Preferred Term
Lowest Level Term
Myocardial Infarction
Heart attack
Ischaemic coronary
artery disorders
![Page 37: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/37.jpg)
Structural Hierarchy of the MedDRA Terminology
System Order Class
High Level Group Term
High Level Term
Preferred Term
Lowest Level Term
Myocardial Infarction
Heart attack
Ischaemic coronary
artery disorders
Coronary artery disorders
Cardiac Disorders
![Page 38: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/38.jpg)
Problems with MedDRA
• difficulties coding – lack of information
![Page 39: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/39.jpg)
Events difficult to codee.g. “swollen ankles”
![Page 40: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/40.jpg)
“Swollen ankles”Option 1
• Joint swelling PT
• Joint related signs & symptoms HLT
• Joint disorders HLGT
• Musculoskeletal and SOC
connective tissue disorders
![Page 41: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/41.jpg)
“Swollen ankles”Option 2
• Peripheral oedema PT
• Heart failure signs & Symptoms HLT
• Heart Failures HLGT
• Cardiac Disorders SOC
![Page 42: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/42.jpg)
“Swollen ankles”Option 3
• Cellulitis PT
• Soft tissue infectionsHLT
• Skin & Subcutaneous infectionsHLGT
• Infections and infestationsSOC
![Page 43: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/43.jpg)
How you can help us?
• Please include as much information as possible when reporting adverse outcomes
![Page 44: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/44.jpg)
What to include?
• A diagnosis if available
• If unsure of diagnosis, please describe specific signs and symptoms– (not a ?? Please)
• Results of investigations – e.g. endoscopy, lab reports
![Page 45: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/45.jpg)
What to include?
• Any relevant medical history
• Nature of ‘allergic reactions’
• Description of ‘rashes’
• Condition which led to surgery
![Page 46: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/46.jpg)
In conclusion
• Good quality detailed information on adverse events is essential
• Key outcome of BADBIR is evaluation of long term safety of biologic therapy
• Collection of information on adverse will fulfill aims of BADBIR
• Ultimately lead to provision of better quality information to patients
![Page 47: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/47.jpg)
Questions
Pharmacovigilance Team
Miss Victoria WildeDrug Safety Assistant
Mrs Laura WoolfsonPharmacovigilance Manager
Tel: 0161 306 1896, Fax: 0161 306 [email protected]
Dr Elise KleynPharmacovigilance Medical Advisor
![Page 48: British Association of Dermatologists Biologic Interventions Register (BADBIR) Adverse Events](https://reader036.vdocument.in/reader036/viewer/2022062802/56649ea05503460f94ba3a05/html5/thumbnails/48.jpg)
• The dermatology teams for their efforts in registering patients
• BAD was provided with restricted income financial support from Abbott, Wyeth, and Schering Plough to set-up BADBIR
• BAD commissioned the University of Manchester to set-up BADBIR with this financial support
Acknowledgements